The CureVac NV stockpile fell after a preliminary analysis of a medical trial found the COVID-19 vaccine was only 47% effective, well below the target set by other RNA vaccines.
And the German company announced in a statement that the study analyzed 134 cases of coronavirus infection among 40,000 volunteers. CureVac declined to say how many of those who contracted the disease got the vaccine or how many got a placebo. However, the results suggest that the vaccine is less effective for the elderly than for the younger population, Director of Technology Mariola Foten-Mlicic acknowledged.
The study analyzed 134 cases of coronavirus infection among 40,000 volunteers
Although the results are preliminary, they raise questions about the future of the vaccine, as wealthy nations around the world make efforts to vaccinate their populations as quickly as possible with the vaccines that are already available. However, CureVac’s CEO said, CureVac will finish the study and plan to seek approval from the authorities. “Vaccines are urgently needed and I believe we can still contribute,” he insisted.
The vaccine can be very useful for developing countries, because it does not require the deep freezing that other versions require.
CureVac, which is partly owned by the German government, has established partnerships with Bayer AG, GlaxoSmithKline Plc and the UK government with the goal of accelerating production of its vaccine and future versions targeting mutated strains.